Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Advanced or Refractory Solid Malignancies”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Study completedNCT00839631
What this trial is testing

Dose Escalation Study of EC D-3263 HCl in Advanced Solid Tumors

Who this might be right for
Solid Tumors
Dendreon 23
Early research (Phase 1)Study completedNCT01830816
What this trial is testing

Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Participants With Normal Renal Function or Severe Renal Impairment

Who this might be right for
Multiple MyelomaAdvanced Solid Tumors
Millennium Pharmaceuticals, Inc. 41
Testing effectiveness (Phase 2)Study completedNCT01588821
What this trial is testing

Cabozantinib in Advanced Solid Malignancies

Who this might be right for
Lung CancerSolid Tumor (Not Breast or Prostate Cancers)
Massachusetts General Hospital 37
Testing effectiveness (Phase 2)Active Not RecruitingNCT04266912
What this trial is testing

Avelumab and M6620 for the Treatment of DDR Deficient Metastatic or Unresectable Solid Tumors

Who this might be right for
Metastatic Malignant Solid NeoplasmRefractory Malignant Solid NeoplasmUnresectable Malignant Solid Neoplasm
M.D. Anderson Cancer Center 23
Early research (Phase 1)Study completedNCT03510104
What this trial is testing

Pharmacokinetic and Safety Study of MRX-2843 in Adults With Relapsed/Refractory Advanced and/or Metastatic Solid Tumors

Who this might be right for
Advanced CancerMetastatic CancerNeoplasms+3 more
Meryx, Inc. 42
Testing effectiveness (Phase 2)Study completedNCT03233204
What this trial is testing

Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)

Who this might be right for
Advanced Malignant Solid NeoplasmAnn Arbor Stage III Childhood Non-Hodgkin LymphomaAnn Arbor Stage IV Childhood Non-Hodgkin Lymphoma+33 more
National Cancer Institute (NCI) 6
Early research (Phase 1)Study completedNCT05040932
What this trial is testing

Study of YH004 (4-1BB Agonist Antibody) in Advanced or Metastatic Malignancy

Who this might be right for
Cancer
Eucure (Beijing) Biopharma Co., Ltd 8
Early research (Phase 1)Looking for participantsNCT07106827
What this trial is testing

GV20-0251 in Advanced or Refractory Solid Tumors

Who this might be right for
HCC - Hepatocellular CarcinomaCholangiocarcinomaMelanoma+5 more
West China Hospital 10
Early research (Phase 1)Ended earlyNCT03871855
What this trial is testing

SHR-1702 Alone or With Camrelizumab in Participants With Advanced Relapsed/Refractory Solid Tumors

Who this might be right for
Advanced Solid Tumor
Jiangsu HengRui Medicine Co., Ltd. 8
Testing effectiveness (Phase 2)Looking for participantsNCT02332668
What this trial is testing

Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)

Who this might be right for
MelanomaLymphomaSolid Tumor+2 more
Merck Sharp & Dohme LLC 370
Early research (Phase 1)Ended earlyNCT00511576
What this trial is testing

Study to Evaluate Combination Treatment of MGCD0103 and Docetaxel (Taxotere®) for Subjects With Advanced Cancer Tumors

Who this might be right for
Breast CancerLung CancerPulmonary Cancer+5 more
Mirati Therapeutics Inc. 54
Early research (Phase 1)Study completedNCT02592785
What this trial is testing

Phase I Dose Escalation Study of BAY 1163877 (Rogaratinib) in Japanese Subjects With Refractory, Locally Advanced or Metastatic Solid Tumors

Who this might be right for
Neoplasms
Bayer 9
Early research (Phase 1)UnknownNCT05650580
What this trial is testing

TR115 in Patients With Relapsed / Refractory Non-Hodgkin's Lymphoma or Advanced Solid Tumors

Who this might be right for
Non-Hodgkin's Lymphoma, RelapsedNon-Hodgkin's Lymphoma RefractoryAdvanced Solid Tumor
Tarapeutics Science Inc. 26
Early research (Phase 1)Looking for participantsNCT05892718
What this trial is testing

A Safety and Efficacy Study of HCB101, Fc-fusion Protein Targeting SIRPα-CD47 Pathway, in Solid or Hematological Tumors

Who this might be right for
Advanced Solid TumorRefractory Non-Hodgkin Lymphoma
FBD Biologics Limited 80
Early research (Phase 1)Looking for participantsNCT05341557
What this trial is testing

BPI-371153 in Subjects with Advanced Solid Tumors or Relapsed/Refractory Lymphoma

Who this might be right for
Advanced Solid TumorLymphomaNSCLC+1 more
Betta Pharmaceuticals Co., Ltd. 110
Early research (Phase 1)Looking for participantsNCT05039801
What this trial is testing

IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors

Who this might be right for
Advanced Endometrial CarcinomaAdvanced Head and Neck Squamous Cell CarcinomaAdvanced Malignant Solid Neoplasm+35 more
M.D. Anderson Cancer Center 54
Early research (Phase 1)Study completedNCT01346358
What this trial is testing

IMC-CS4 in Subjects With Advanced Solid Tumors

Who this might be right for
Neoplasms
Eli Lilly and Company 52
Early research (Phase 1)Study completedNCT01340040
What this trial is testing

Dose-escalation Study to Assess Safety, Tolerability and Pharmacokinetics of MEDI-573 in Japanese Subjects

Who this might be right for
CancerAdvanced Solid Malignancies
AstraZeneca 10
Early research (Phase 1)Study completedNCT00207012
What this trial is testing

MAD Refractory: Solid Tumor QD w/o Break

Who this might be right for
HER2 or EGFR Expressing Advanced Solid Malignancies
Bristol-Myers Squibb 45
Early research (Phase 1)Study completedNCT00676299
What this trial is testing

A Safety and Dose-finding Study of JNJ-26483327, a Drug in Development for Cancer, for Patients With Advanced and/or Refractory Solid Malignancies.

Who this might be right for
Protein Kinase InhibitorsAntineoplastic ProtocolsClinical Trial, Phase 1+4 more
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 19
Next Page